Metabolic · Investigational
Taspoglutide
No lawful US pathway
01 · Overview
Taspoglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist derived from human GLP-1 with amino acid substitutions designed to resist dipeptidyl peptidase-4 degradation and extend duration of action. The peptide activates GLP-1 receptors to promote glucose-dependent insulin secretion, inhibit glucagon release, and slow gastric emptying.
It was developed as a once-weekly subcutaneous injection for type 2 diabetes but never received regulatory approval (PMID 23139373).
02 · Research summary & key findings
In the T-emerge phase 3 program, once-weekly taspoglutide lowered HbA1c by about 1.0 to 1.2 percent versus 0.1 percent with placebo in drug-naive patients (Diabetes Care, 2012) (PMID 22301126). In the T-emerge 2 trial it lowered HbA1c more than twice-daily exenatide, but with high rates of nausea and vomiting, more injection-site and systemic allergic reactions, and anti-taspoglutide antibodies in 49 percent of patients, which the authors judged unacceptable (PMID 23139373). Development was stopped because of gastrointestinal intolerance and serious hypersensitivity reactions; a pooled analysis of nine T-emerge trials found no excess short-term cardiovascular risk (PMID 25656522).
03 · Regulatory status
Taspoglutide is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Taspoglutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Taspoglutide is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
References
- [1]Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1) Diabetes Care, 2012. PMID 22301126
- [2]The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial Diabetes Care, 2013. PMID 23139373
- [3]Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials Diabetes Obes Metab, 2015. PMID 25656522
Primary literature
- PubMed: "Taspoglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Taspoglutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Taspoglutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.